Roivant Sciences portfolio company Kinevant Sciences today revealed its Phase II study failed to show treatment benefit in ...

Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics (Nasdaq: KROS) to ...

China's National Medical Products Administration (NMPA) has granted conditional approval for a combination therapy of Elunate ...

US privately-held biotech COUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Roche ...

The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing ...

Atom Therapeutics partners with China Medical System to commercialize lingdolinurad for gout and hyperuricemia in China, Hong ...

US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies ...

Senti Biosciences reports promising Phase I results for SENTI-202 in acute myeloid leukemia, with two of three patients ...

Licensing agreement deal value for innovative T-cell receptor (TCR) immunotherapy drugs surged in 2024, with European ...

Bausch Health has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D.

New results from the RESOLUTION trial demonstrate the efficacy of Vyepti (eptinezumab) on top of patient education for ...